FierceBiotech 2026年6月2日 ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
FierceBiotech 2026年6月2日 ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray
FierceBiotech 2026年6月2日 MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs
FierceBiotech 2026年6月2日 Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial
FierceBiotech 2026年6月2日 ASCO: Takeda touts ‘tremendous potential’ of Innovent’s PD-1/IL-2 bispecific after seeing survival data
FierceBiotech 2026年6月1日 ASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas
FierceBiotech 2026年6月1日 Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo
FierceBiotech 2026年6月1日 Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
FierceBiotech 2026年6月1日 Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline
FierceBiotech 2026年6月1日 Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear
FierceBiotech 2026年6月1日 Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome
FierceBiotech 2026年5月31日 ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout